FOXP3 and neoplasm: In vivo experiments demonstrated that BN1 effectively reduced tumor burden while exhibiting immunostimulatory effects, including the increase of CD8+ IFNγ+ cells, the decrease of CD4+ Foxp3+ cells, and the regulation of cytokines.